Physician profile
Pedro Lopez
NPI 1962410480
$8,194.26
in general payments reported to CMS, 2019-2025
31 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $276 · 2021: $719 · 2022: $1,384 · 2023: $1,706 · 2024: $1,719 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,333.73 | 2019-2025 | Simbrinza, Clareon, Dailies Total1 |
| Regeneron Healthcare Solutions, INC. | $829.77 | 2019-2025 | Eylea, Eylea Hd |
| Mallinckrodt Hospital Products INC. | $797.48 | 2020-2025 | Acthar |
| Bausch & Lomb Americas INC. | $736.88 | 2022-2025 | Miebo, Vyzulta, Prolensa |
| Sun Pharmaceutical Industries INC. | $610.14 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $402.51 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $377.78 | 2024-2025 | Vevye, Triesence |
| Genentech USA, INC. | $344.79 | 2019-2025 | Vabysmo |
| Astellas Pharma US INC | $330.43 | 2023-2025 | Izervay |
| Rayner Intraocular Lenses Limited | $313.36 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Apellis Pharmaceuticals, INC. | $260.63 | 2023-2025 | Syfovre |
| Thea Pharma INC. | $221.67 | 2023-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $211.96 | 2020-2022 | |
| Biotissue Holdings INC. | $202.48 | 2022-2025 | |
| Horizon Therapeutics Plc | $188.14 | 2021-2023 | Tepezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.73 | 2019-2021 | |
| Allergan, INC. | $115.19 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $113.54 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $113.27 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $92.22 | 2024-2025 | Iluvien, Purified Cortrophin Gel |
| Eyepoint US, INC. | $81.43 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $79.89 | 2021-2025 | Xeomin |
| Glaukos Corporation | $47.95 | 2025 | Idosetr |
| Abbvie INC. | $47.26 | 2023 | |
| Sight Sciences, INC. | $40.00 | 2022 | |
| Immunocore Limited | $30.33 | 2023 | Kimmtrak |
| Dutch Ophthalmic, USA | $26.44 | 2022 | |
| Oyster Point Pharma, INC. | $23.42 | 2022 | |
| Dompe US, INC. | $23.14 | 2022 | |
| Amgen INC. | $21.54 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $16.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.